Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service

Abstract

ObjectiveThe main objective of this study was to explore the extent to which the incremental cost-effectiveness ratio (ICER), alongside other factors, predicts the final outcome of medicine price negotiation in Italy. The second objective was to depict the mean ICER of medicines obtained after negotiation. Methods Data were extracted from company dossiers submitted to the Italian Medicines Agency (AIFA) from October 2016 to January 2021 and AIFA's internal database. Beta-based regression analyses were used to test the effect of ICER and other variables on the outcome of price negotiation (ΔP), defined as the percentage difference between the list price requested by manufacturers and the final price paid by the Italian National Health Service (INHS). Results In our dataset of 48 pricing and reimbursement procedures, the ICER before negotiation was one of the variables with a major impact on the outcome of negotiation when ≥ 40,000€/QALY. As resulting from multiple regression analyses, the effect of the ICER on ΔP seemed driven by medicines for non-onco-immunological and non-rare diseases. Overall, the negotiation process granted mean incremental costs of €64,688 and mean incremental QALYs of 1.96, yielding an average ICER of €33,004/QALY. Conclusions This study provides support on the influence of cost-effectiveness analysis on price negotiation in the Italian context, providing an estimate of the mean ICER of reimbursed medicines, calculated using net confidential prices charged by the INHS. The role and use of economic evaluations in medicines pricing should be further improved to get the best value for money.

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

“…Considering a WTP of €40,000/QALY ( 38 ), the baseline findings show Cab to have high cost utility and endoscopic surgery just a tad above that.…”

“…Regarding the ICER for endoscopic surgery, it was estimated to be €44,846.64, representing the additional cost per QALY gained compared to Cab treatment. The baseline findings reveal that endoscopic surgery is just slightly above the WTP threshold of €40,000/QALY in the reference economy ( 38 ), while Cab proves to have high cost utility. These updated results provide valuable insights for decision-makers in choosing the most efficient treatment options for patients with microP.…”

“…After completing the full cost calculation using the micro-costing approach, a cost-utility analysis (CUA) ( 32 ) was carried out to estimate the value for money profile of the treatments for microP patients in the Italian healthcare setting considering a willingness-to-pay (WTP) of €40,000/quality-adjusted life year (QALY) gained ( 26 , 38 ).…”

COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

“…While the impact of high initial proposed pricing should at least still be partially captured by the dichotomous variable of confidential discount, which is a negotiation tool to decrease drug acquisition costs, other aspects that could have an impact on negotiation outcomes remain unexplored. For example, Russo et al ( 17 ) find that incremental cost-effectiveness ratio (ICER) resulting from the economic evaluation of a drug is a predictor of its final price outcome, and it might play a role in the drugs’ TTM as well.…”

Multi-dimensional Perspective Pharmaceutical Evaluation: A Path to Enhancing Healthcare Decision-Making in Real-World

“…Compared to countries focusing on a single dimension, typically innovative drugs, 6 China's approach introduces some differences regarding the evaluation criteria. In this classification of drugs, you can get a panoramic view of any drug, with the following five advantages:…”